Pharmaceutical

Adamas Pharmaceuticals (Nasdaq:ADMS), a fully-integrated pharmaceutical company pioneering time-dependent medicines for central nervous system (CNS) disorders, today announced that pooled Phase 3 data of GOCOVRI (amantadine) extended release capsules were published online in Parkinsonism and Related Disorders. As quoted in the press release: The paper entitled, Impact of dyskinesia on activities of daily living in Parkinson’s disease: …

Adamas Pharmaceuticals (Nasdaq:ADMS), a fully-integrated pharmaceutical company pioneering time-dependent medicines for central nervous system (CNS) disorders, today announced that pooled Phase 3 data of GOCOVRI (amantadine) extended release capsules were published online in Parkinsonism and Related Disorders.

As quoted in the press release:

The paper entitled, Impact of dyskinesia on activities of daily living in Parkinson’s disease: Results from pooled Phase 3 ADS-5102 clinical trials, concluded that dyskinesias in people with Parkinson’s disease can impact a patient’s activities of daily living (ADLs) across multiple tasks, and that treatment with GOCOVRI can help ameliorate the impairment.

GOCOVRI is the first and only medicine approved by the U.S. Food and Drug Administration (FDA) for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications. It is also the only drug approved by the FDA to treat dyskinesia in people with Parkinson’s disease on levodopa therapy, as well as demonstrate a secondary benefit in reducing OFF time in that population.

“Dyskinesia in people with Parkinson’s disease is a levodopa dose-limiting consequence of disease progression and chronic levodopa therapy, which can impair ADLs across multiple tasks,” said Rajesh Pahwa, M.D., Laverne & Joyce Rider Professor of Neurology and Director of the Parkinson’s Disease and Movement Disorder Center at the University of Kansas Medical Center. “The management of Parkinson’s disease primarily focuses on the patient’s OFF time, and because the impact of dyskinesia on ADLs has not been extensively studied it may be underappreciated by patients and their physicians. Further studies integrating quality of life measures should be undertaken to more fully characterize the impairment and integrate these findings into Parkinson’s disease management plans.”

Click here to read the full press release.

MARKETS

Markets
TSX19392.69+134.37
TSXV650.73-1.63
DOW31487.70+49.44
S&P 5003894.66-5.45
NASD11435.26-89.29
ASX6706.00+177.60

COMMODITIES

Commodities
Gold1821.20-2.23
Silver20.96-0.20
Copper3.78+0.01
Palladium1881.50+13.50
Platinum918.00+11.00
Oil109.83+0.26
Heating Oil4.03-0.09
Natural Gas6.63+0.13

DOWNLOAD FREE REPORTS

×